Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) - Total Assets
Based on the latest financial reports, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) holds total assets worth €10.44 Billion EUR (≈ $12.20 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited - Total Assets Trend (2013–2025)
This chart illustrates how Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's total assets have evolved over time, based on quarterly financial data. Also see Tianjin Zhong Xin Pharmaceutical Group C market cap and net worth for the company's overall valuation and market capitalisation.
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited - Asset Composition Analysis
Current Asset Composition (December 2025)
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's total assets of €10.44 Billion consist of 61.2% current assets and 38.8% non-current assets. Review Tianjin Zhong Xin Pharmaceutical Group C total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 8.7% |
| Accounts Receivable | €973.20 Million | 8.3% |
| Inventory | €1.13 Billion | 9.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €311.15 Million | 2.7% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Tianjin Zhong Xin Pharmaceutical Group C (2TZ) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's current assets represent 61.2% of total assets in 2025, an increase from 60.6% in 2013.
- Cash Position: Cash and equivalents constituted 8.7% of total assets in 2025, down from 10.4% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 3.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 9.7% of total assets.
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Competitors by Total Assets
Key competitors of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥29.95 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Shenzhen Kangtai Biological Products Co Ltd
SHE:300601
|
China | CN¥13.93 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC
|
India | Rs3.22 Billion |
|
ChengDa Pharmaceuticals Co. Ltd.
SHE:301201
|
China | CN¥2.35 Billion |
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.16 | 2.00 | 2.48 |
| Quick Ratio | 1.78 | 1.58 | 1.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €3.29 Billion | €2.85 Billion | €3.63 Billion |
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited - Advanced Valuation Insights
This section examines the relationship between Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.28 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | 8.6% |
| Total Assets | €11.69 Billion |
| Market Capitalization | $692.11 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's assets grew by 8.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2013–2025)
The table below shows the annual total assets of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €11.69 Billion ≈ $13.67 Billion |
+8.55% |
| 2024-12-31 | €10.77 Billion ≈ $12.59 Billion |
+5.26% |
| 2023-12-31 | €10.23 Billion ≈ $11.96 Billion |
+0.72% |
| 2022-12-31 | €10.16 Billion ≈ $11.87 Billion |
+12.02% |
| 2021-12-31 | €9.07 Billion ≈ $10.60 Billion |
+9.46% |
| 2020-12-31 | €8.28 Billion ≈ $9.68 Billion |
+5.61% |
| 2019-12-31 | €7.84 Billion ≈ $9.17 Billion |
+10.38% |
| 2018-12-31 | €7.11 Billion ≈ $8.31 Billion |
+7.30% |
| 2017-12-31 | €6.62 Billion ≈ $7.74 Billion |
+4.11% |
| 2016-12-31 | €6.36 Billion ≈ $7.44 Billion |
+4.81% |
| 2015-12-31 | €6.07 Billion ≈ $7.10 Billion |
+11.62% |
| 2014-12-31 | €5.44 Billion ≈ $6.36 Billion |
+3.32% |
| 2013-12-31 | €5.26 Billion ≈ $6.15 Billion |
-- |
About Tianjin Zhong Xin Pharmaceutical Group Corporation Limited
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People's Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and… Read more